Following radiotherapy, tumor-derived MPs from breast carcinoma cells carry elevated levels of immune-modulating proteins, including PD-L1, and are delivered to cytotoxic T lymphocytes (CTLs) (95). The gene discussed is CD274; the disease is breast carcinoma.